Efficacy of Dendritic Cell-Cytokine Induced Killer Cells combined with concurrent chemoradiotherapy on Locally Advanced Non- Small Cell Lung Cancer (LANSCLC)

Survival Time

Survival Time



This study aims to explore the efficacy and safety of docetaxel/cisplatin concurrent chemoradiotherapy (CCRT) Combined with dendritic cell-cytokine induced killer cell (DC-CIK) immunotherapy in the treatment of patients diagnosed with locally advanced non-small cell lung cancer.The results reveal that the combined treatment can significantly improve cellular immunity, long-term survival rate and raised the quality of life for patients with LANSCLC.

Patients characteristics

A total of 142 patients with LANSCLC, those in stage IIIA and IIIB, those with normal function in the hematopoietic system, liver, kidney and heart. Those age 75 years old and treated with the first treatment without a history of Radiotherapy and Chemotherapy. This study is divided into 2 groups, 71 patients in Docetaxel/Cisplatin CCRT group and 71 patients in CCRT combined with DC-CIK IMT group.


• Blood was drawn to isolate the autologous peripheral blood mononuclear cells (PBMCs), 100 mL of serum was culture in RPMI-1640 complete medium and the cell concentration was adjusted. • The cytokines were complemented and recombinant human tumor necrosis factor alpha (TNF-) was added to induce the maturation of DCs.
• The tumor cell antigen was prepared and CIKs were induced.
• About 1×1010 DC-CIKs were collected and cultured at 12-14 d, centrifuged at 500 g for
10 mins, washed for 3 times, and resuspended in 200 mL normal saline and
supplemented with 2.5 mL of 20% human albumin.


All patients underwent CCRT, Docetaxel was Intravenously infused (75mg/m2) on day 1 and Cisplatin was Intravenously infused (25mg/m2) on 1-3 day for total of 4 cycles (28 d as 1 cycle) DC-CIK was Intravenously infused back to the patient within 1 hour, the DC-CIK group received 4 cycles of Chemotherapy and 2 cycles of DC-CIK Immunotherapy.


• Short term efficacy: in DC-CIK group were 23 patients (32.4%) had Complete Response (CR), 36 (50.7%) had partial response, 9 (12.7%) had stable disease and 3 (4.2%) had Progressive disease (PD)
• There is no significant difference were found on KPS and QoL scores between the 2 groups in 6 months after treatment.
• After 12 months of treatment, the DC-CIK group were evidently higher compared to CCRT group.


Docetaxel/Cisplatin CCRT combined with DC-CIK Immunotherapy can significantly enhance the cellular immunity, improved the long-term survival rate and raise quality of life of the patients with LANSCLC with tolerable adverse effects.

Article Reference link: click here

Scientific article publishing date 13/1/2017

Immucura identifier BSC21_030EN